BioView Ltd. (IL:BIOV)
TASE:BIOV
BIOV Stock Chart & Stats
20.00
<0.01(3.10%)
At close: 4:00 PM EST
20.00
<0.01(3.10%)
Day’s Range― - ―
52-Week Range103.00 - 294.00
Previous CloseN/A
Volume9.67K
Average Volume (3M)133.91K
Market Cap
₪15.24M
Enterprise Value11.95M
Total Cash (Recent Filing)₪7.84M
Total Debt (Recent Filing)₪1.86M
Price to Earnings (P/E)―
Beta>-0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding13,898,633
10 Day Avg. Volume180,532
30 Day Avg. Volume133,914
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.41
Price to Sales (P/S)1.14
P/FCF Ratio-7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BIOV FAQ
What was BioView Ltd.’s price range in the past 12 months?
BioView Ltd. lowest stock price was 103.00 and its highest was 294.00 in the past 12 months.
What is BioView Ltd.’s market cap?
BioView Ltd.’s market cap is ₪15.24M.
When is BioView Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioView Ltd.’s earnings last quarter?
Currently, no data Available
Is BioView Ltd. overvalued?
According to Wall Street analysts BioView Ltd.’s price is currently Overvalued.
Does BioView Ltd. pay dividends?
BioView Ltd. pays a Notavailable dividend of 200 which represents an annual dividend yield of N/A. See more information on BioView Ltd. dividends here
What is BioView Ltd.’s EPS estimate?
BioView Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioView Ltd. have?
BioView Ltd. has 13,898,633 shares outstanding.
What happened to BioView Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioView Ltd.?
Currently, no hedge funds are holding shares in IL:BIOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioView Ltd.
Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and research laboratories worldwide, specifically in the fields of cytology, cytogenetics, and pathology. The company's extensive product lineup includes: Accord: A semi-automated fluorescent imaging and analysis workbench microscope station. Accord Plus: An automatic fluorescent imaging system capable of real-time scanning, analysis, and sorting of diverse FISH (Fluorescence In Situ Hybridization) samples. Allegro Plus: Another automatic fluorescent imaging system engineered to pinpoint various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. DUET-3: An imaging and analysis platform featuring an automated barcode reader, which streamlines the processing of multiple test types within a single scan batch. DeNovo: An automated scanning system dedicated to the precise detection, analysis, and characterization of circulating tumor cells found in peripheral blood. Solo Workstation & Solo Touch Workstation: These are offline and standalone workstations, respectively, providing advanced tools for reviewing and analyzing test results remotely from the microscope. SoloWeb: A comprehensive web-based solution that enables remote analysis, reporting, and expert consultation on cases scanned using Bio-View's systems. Furthermore, Bio-View Ltd has established a strategic partnership with ANGLE plc to jointly develop a liquid biopsy circulating tumor cell HER2 assay, specifically targeting breast cancer.